Cellebrite DI Ltd. (NASDAQ:CLBT) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have earned an average rating of “Moderate Buy” from the five brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $22.50.

Several equities analysts have recently issued reports on CLBT shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellebrite DI in a report on Monday, December 29th. JPMorgan Chase & Co. lifted their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Wall Street Zen lowered shares of Cellebrite DI from a “hold” rating to a “sell” rating in a research note on Saturday. Needham & Company LLC decreased their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Finally, Lake Street Capital raised their price target on shares of Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, November 13th.

Cellebrite DI Trading Up 0.7%

Shares of NASDAQ CLBT opened at $15.30 on Friday. The company has a market cap of $3.82 billion, a price-to-earnings ratio of 49.35, a price-to-earnings-growth ratio of 2.35 and a beta of 1.30. Cellebrite DI has a 12-month low of $11.76 and a 12-month high of $20.86. The stock’s 50 day simple moving average is $15.61 and its 200 day simple moving average is $16.95.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Wednesday, February 11th. The company reported $0.14 EPS for the quarter, hitting analysts’ consensus estimates of $0.14. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The firm had revenue of $128.82 million during the quarter, compared to the consensus estimate of $126.07 million. During the same period in the prior year, the business earned $0.10 EPS. The firm’s revenue was up 28.8% on a year-over-year basis. As a group, equities analysts forecast that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cellebrite DI

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Financial Management Professionals Inc. acquired a new position in Cellebrite DI during the 3rd quarter worth $28,000. CWM LLC raised its stake in shares of Cellebrite DI by 85.7% during the third quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after purchasing an additional 720 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Cellebrite DI by 1,998.0% during the second quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock valued at $34,000 after purchasing an additional 1,998 shares in the last quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its holdings in Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after purchasing an additional 850 shares during the period. Finally, Toth Financial Advisory Corp bought a new position in Cellebrite DI in the 3rd quarter valued at about $38,000. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.